Prior CAD, valvular disease, and diabetes are not associated with increased risk of AF [33], while previous use of angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), beta-blockers, and aspirin are associated with increased risk of AF in patients treated with ibrutinib [34]. The gene discussed is ACE; the disease is atrial fibrillation.